relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and
Company profile
Ticker
RLMD
Exchange
Website
CEO
Sergio Traversa
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CAMP NINE, INC.
SEC CIK
RLMD stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
8-K
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Departure of Directors or Certain Officers
11 Jan 24
8-K
Relmada Therapeutics Provides Corporate Update
4 Jan 24
8-K
Departure of Directors or Certain Officers
3 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
11 Oct 23
Transcripts
RLMD
Earnings call transcript
2023 Q3
8 Nov 23
RLMD
Earnings call transcript
2023 Q2
8 Aug 23
RLMD
Earnings call transcript
2023 Q1
11 May 23
RLMD
Earnings call transcript
2022 Q4
23 Mar 23
RLMD
Earnings call transcript
2022 Q3
10 Nov 22
RLMD
Earnings call transcript
2022 Q2
14 Aug 22
RLMD
Earnings call transcript
2022 Q1
8 May 22
RLMD
Earnings call transcript
2021 Q4
24 Mar 22
RLMD
Earnings call transcript
2021 Q3
12 Nov 21
RLMD
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
SC 13G/A
PERCEPTIVE ADVISORS LLC
6 Mar 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
SERGIO TRAVERSA
31 Jan 24
4
Maged Shenouda
31 Jan 24
4
Chuck Ence
31 Jan 24
4
SERGIO TRAVERSA
19 Dec 23
4
Maged Shenouda
19 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.70 mm | 6.70 mm | 6.70 mm | 6.70 mm | 6.70 mm | 6.70 mm |
Cash burn (monthly) | 2.59 mm | 2.99 mm | 7.56 mm | (no burn) | 3.88 mm | 6.44 mm |
Cash used (since last report) | 17.30 mm | 19.94 mm | 50.53 mm | n/a | 25.90 mm | 43.03 mm |
Cash remaining | -10.60 mm | -13.24 mm | -43.83 mm | n/a | -19.20 mm | -36.33 mm |
Runway (months of cash) | -4.1 | -4.4 | -5.8 | n/a | -5.0 | -5.6 |
Institutional ownership, Q2 2023
61.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 95 |
Opened positions | 20 |
Closed positions | 15 |
Increased positions | 22 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 35.78 bn |
Total shares | 18.57 mm |
Total puts | 137.90 k |
Total calls | 95.80 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Deep Track Capital | 2.84 mm | $6.98 bn |
Venrock Healthcare Capital Partners II | 2.27 mm | $0.00 |
RTW Investments | 2.13 mm | $5.24 bn |
Vanguard | 1.31 mm | $3.22 bn |
Acadian Asset Management | 1.22 mm | $3.00 mm |
Parsons Capital Management | 873.31 k | $2.15 bn |
Palo Alto Investors | 732.40 k | $1.80 bn |
BLK Blackrock | 605.25 k | $1.49 bn |
Citadel Advisors | 587.79 k | $1.45 bn |
Millennium Management | 343.98 k | $846.18 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | Chuck Ence | Common Stock | Buy | Acquire P | No | No | 4.0548 | 13,670 | 55.43 k | 38,970 |
31 Jan 24 | Sergio Traversa | Common Stock | Buy | Acquire P | No | No | 3.9968 | 27,460 | 109.75 k | 244,024 |
31 Jan 24 | Maged Shenouda | Common Stock | Buy | Acquire P | No | No | 4.0645 | 6,875 | 27.94 k | 34,903 |
30 Jan 24 | Chuck Ence | Common Stock | Buy | Acquire P | No | No | 3.8657 | 14,500 | 56.05 k | 25,300 |
30 Jan 24 | Sergio Traversa | Common Stock | Buy | Acquire P | No | No | 3.9013 | 40,999 | 159.95 k | 216,564 |
30 Jan 24 | Maged Shenouda | Common Stock | Buy | Acquire P | No | No | 3.8882 | 15,000 | 58.32 k | 28,028 |
29 Jan 24 | Chuck Ence | Common Stock | Buy | Acquire P | No | No | 3.6517 | 10,800 | 39.44 k | 10,800 |
29 Jan 24 | Sergio Traversa | Common Stock | Buy | Acquire P | No | No | 3.7106 | 31,541 | 117.04 k | 175,565 |
29 Jan 24 | Maged Shenouda | Common Stock | Buy | Acquire P | No | No | 3.6528 | 10,800 | 39.45 k | 13,028 |
15 Dec 23 | Fabiana Fedeli | Stock Option Common Stock | Grant | Acquire A | No | No | 2.48 | 31,522 | 78.17 k | 31,522 |